Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Hims Hers Health

Stock Market Today: Dow Jones Pops After Trade Deal News; A Genetic Testing Stock Breaks Out (Live Coverage)

The Dow Jones led the major indexes Tuesday afternoon as the Nasdaq lagged. Coca-Cola and Pfizer stocks jumped on the stock market today.

Investors Business Daily

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

MarketBeat

Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch

Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Stock Market Suffers Sharp Losses As Nvidia, Tesla Dive; Nutanix Jumps: Weekly Review

The Nasdaq sold off for the week, fighting for last-ditch support. The Dow Jones held its own.

Investors Business Daily

Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up

Hims & Hers Health put out a jaw dropping commercial. Now, Hims stock is just dropping, as its semaglutide business faces a setback.

Investors Business Daily

Stock Market Today: Dow Jones Improves; Tesla Skids Again While Techs Keep Tumbling (Live Coverage)

The Dow Jones index pulled ahead as the other major indexes fell on the stock market today. Tesla and a number of tech stocks continued long losing streaks.

Investors Business Daily

Dow Jones Rises As Trump Tariffs 'Going Forward;' Hims Stock Crashes On Earnings

The Dow Jones rose as President Trump's tariffs on Canada and Mexico are "going forward." Hims stock crashed on the stock market today.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Hims & Hers: From Viral Ad to Volatile Stock

Hims & Hers leverages its viral Super Bowl advertisement and strategic weight loss market entry to achieve stock gains and brand recognition in telehealth.

MarketBeat

Hims & Hers Option Trade Offers $410 Return Or 17% Discount

The goal is to either have the put expire worthless and keep the premium, or be assigned and acquire the stock below the current price.

Investors Business Daily

Where Hims & Hers Health Stands With Analysts

Analysts' ratings for Hims Hers Health (NYSE:HIMS) over the last quarter vary from bullish to bearish, as provided by 10 analysts.

Benzinga

Spotlight on Hims & Hers Health: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Hims Hers Health (NYSE:HIMS), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HIMS usually suggests something big…

Benzinga

Exclusive: The COO of Hims & Hers was the third person to try their GLP-1 drugs—and she's ready to share her story

Health executive Melissa Baird is dedicated to breaking the stigma of weight management at work.

Fortune

Is Hims & Hers Stock a Buy for GLP-1 Upside?

Hims & Hers is a digital health company that is firing on all cylinders, while improving its profit margins at a robust pace.

Barchart

Stock Market Today: Stocks Rise as Fed Speakers Speak and Nvidia Awaits

Markets eked out gains in a low-volume session that was more focused on upcoming earnings from NVDA.

Kiplinger

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

HIMS Stock Breaks Out On Powerful Turnaround Quarter

HIMS stock sees its Relative Strength Rating reach the 80-plus level.

Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022

Upgrades

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

3 Stocks Under $5 Insiders Are Aggressively Buying

U.S. stocks closed sharply lower, with the Nasdaq Composite dipping around 450 on Thursday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Hims & Hers Health's Return On Capital Employed Overview

According to Benzinga Pro data, during Q1, Hims & Hers Health (NYSE:HIMS) posted sales of $101.31 million. Earnings were up 47.85%, but Hims & Hers Health still reported an overall loss of $16.25 million.

Benzinga

Earnings Preview For Hims & Hers Health

Hims & Hers Health (NYSE:HIMS) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Hims & Hers Health will report an earnings per share (EPS) of $-0.07.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.